72
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Remission of disseminated cancer after systemic oncolytic virotherapy.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 10(11) TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved within the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.

          Related collections

          Author and article information

          Journal
          Mayo Clin. Proc.
          Mayo Clinic proceedings
          1942-5546
          0025-6196
          Jul 2014
          : 89
          : 7
          Affiliations
          [1 ] Department of Molecular Medicine, Mayo Clinic, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN.
          [2 ] Department of Molecular Medicine, Mayo Clinic, Rochester, MN.
          [3 ] Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
          [4 ] Department of Radiology, Mayo Clinic, Rochester, MN.
          [5 ] Division of Hematology, Mayo Clinic, Rochester, MN.
          [6 ] Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
          [7 ] Department of Molecular Medicine, Mayo Clinic, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. Electronic address: Dispenzieri.angela@mayo.edu.
          Article
          S0025-6196(14)00332-2 NIHMS637062
          10.1016/j.mayocp.2014.04.003
          24835528
          Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

          Comments

          Comment on this article